IL33 and cancer: By contrast, lung ILC2s show a largely opposite receptor profile compared to intestinal ILC2s, predominantly expressing ST2 but not IL-25R (24), and can either promote or suppress cancer metastasis to the lung in response to IL-33 (50, 51).